← Eichor
Study identifier: NCT06945549 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging

Condition: Inflammatory Bowel Disease (IBD) · Disease Activity · FAPI  ·  Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

PhaseN/A
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to evaluate the role and effect of 18F-FAPI PET imaging in the identification of intestinal lesions and the assessment of disease activity in inflammatory bowel disease. The main question it aims to answer is: Can 18F-FAPI PET imaging effectively identify intestinal lesions in inflammatory bowel disease and accurately assess disease activity? Colonoscopy, enhanced abdominal CT, and 18F-FAPI intestinal imaging were completed within 1 week, and major adverse outcomes (MAO) were followed up 12 months after enrollment. Last updated on March 25, 2025

This description comes directly from the study's public registry record.

Talk to the study team

Wenbo Li, postgraduate  ·  +8615292886778  ·  lwb@tmmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Army Medical Center of PLA, Daping Hospital, Army Medical UniversityChongqing, Chongqing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06945549